A case of incidental STUMP discovery in a patient with concurrent prostatic adenocarcinoma.

Stromal tumours of the prostate are exceedingly rare, often presenting in patients in their fifth decade of life. They are classified as either stromal sarcomas, or stromal tumours of uncertain malignant potential (STUMP), the latter of which is known to have diverse clinical behaviour and thus surgical excision is often warranted. We present a case of a 71-year-old male, initially worked up by his family doctor due to mild obstructive voiding symptoms. Following a more thorough urologic workup, including a prostate biopsy, he was found to have a markedly elevated prostate specific antigen and positive cores on prostate biopsy demonstrating prostatic adenocarcinoma. The decision was made to treat with retropubic radical prostatectomy and bilateral pelvic lymph node dissection. Resulting pathology showed concurrent prostatic adenocarcinoma in addition to STUMP. The patient continues to be followed by oncology as well as a sarcoma specialist due to the unique nature of his case.

Post-transplant lymphoproliferative disorder and management of residual mass post chemotherapy: Case report.

INTRODUCTION: Post-transplant lymphoproliferative disorder (PTLD) is a rare complication. It represents a spectrum of lymphoid proliferations which occur in the setting of immunosuppression and organ transplantation. There are no reported cases or recommendations for the treatment of residual masses post rituximab of PTLD. PRESENTATION OF CASE: A patient with a long standing history of immunosuppression due to multiple kidney transplants starting in 1979, presented with a very large palpable hard abdominal mass (2004) after a fourth renal transplant. There was a past history of heavy immune suppression. CT scans revealed a conglomerate mass involving the right native kidney and two prior right sided renal allografts that crossed the midline. Biopsy of the large right retroperitoneal mass revealed large B cell lymphoma (CD 20 positive); consistent with post-transplant lymphoproliferative disorder (PTLD). DISCUSSION: Management of bulky PTLD, in a highly sensitized, heavily immune suppressed patient is not well described in the literature. The mainstay of therapy is IR and Ritixumab (R) monotherapy and combination R-CHOP. CHOP chemotherapy has an associated mortality rate of up to 38%. Radiotherapy is often considered over surgery and surgery has been most frequently used when associated with bowel complications. In this case report we describe upfront Ritiximab followed by consolidation resection and cytotoxic chemotherapy as a management strategy to reduce toxicity. CONCLUSION: The approach taken by our surgical team illustrates the benefits of disease debulking in certain cases of PTLD, by guiding further therapy and spacing and reducing chemotherapy in immune suppressed patients.

Papillary renal cell carcinoma: report of a rare entity in childhood with review of the clinical management.

We present the case of a 9-year-old boy who presents with gross hematuria and is subsequently diagnosed with a papillary (type 1) renal cell carcinoma. Management of renal cell carcinoma in the pediatric population represents a unique challenge, owing to the potential for a genetic predisposition and screening. Herein we discuss novel discoveries with respect to pediatric renal cell carcinoma and their potential impact on screening.